LAS VEGAS, March 27, 2019
LAS VEGAS, March 27, 2019 /PRNewswire/ --
DelveInsight launched Traveler's Diarrhea - Market Insights, Epidemiology and Market Forecast- 2028
"Around 25%-50% of individuals is expected to experience diarrhea as a result of ingesting fecally contaminated water or food."
Traveler's Diarrhea total market size is calculated by including the market size for both emerging and current therapies. Expected launch of potential therapies may increase Traveler's Diarrhea market size in the coming years, assisted by an increase in diagnosed Traveler's Diarrhea incident population. Owing to the positive outcomes of the several drug candidates during the developmental stage by key players such as Scandinavian Biopharma, Procter and Gamble, etc. they have the potential to create a significant positive shift in the Traveler's Diarrhea Market Size. The United States accounts for the largest Traveler's Diarrhea market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Traveler's Diarrhea treatment therapies comprise of oral hydration and diet modification strategy followed by Anti-motility drugs or antidiarrheal drugs (also known as symptomatic therapy) and Antibiotics/Antimicrobials. The current Traveler's Diarrhea US market is dominated by the use of Antibiotics such as fluoroquinolones comprising ciprofloxacin, ofloxacin, norfloxacin and levofloxacin. Antibioticsforms the first line of treatment. Antibiotics, anti-motility drugs (for symptomatic relief) and Dukarol (Vaccine) are extensively being used as an off label therapy. The current market also holds a single approved therapy Xifaxan by Salix Pharmaceuticals. Xifaxan has shown to capture the market share post approval.
Traveler's Diarrhea current market will increase in the upcoming years with the emergence of several upcoming therapies with prophylactic action and few belonging to the same class of antibiotics and anti-diarrheal agents. The late stage product Bismuth Subsalicylate has emerged as a promising option to enter the Traveler's Diarrhea market in 2021.
Get a demo of the report: https://bit.ly/2JC8VaP
The key players in Traveler's Diarrhea market are:
Table of contents
1 Traveler's Diarrhea Key Insights
2 Traveler's Diarrhea Market Overview at a Glance
3 Traveler's Diarrhea Disease Background and Overview
3.7 Traveler's Diarrhea Diagnosis
4 Traveler's Diarrhea Epidemiology and Patient Population
5 Traveler's Diarrhea Country Wise-Epidemiology
5.1 United States
5.2 EU5 Countries
5.7 United Kingdom
6 Traveler's Diarrhea Treatment
7 Traveler's Diarrhea Unmet Needs
8 Traveler's Diarrhea Marketed Drugs
8.1 Aemcolo/Relafalk: Cosmo Pharmaceuticals
8.2 Xifaxan: Salix Pharmaceuticals
9 Traveler's Diarrhea Emerging Drugs
9.1 Traveler's Diarrhea Key Cross Competition
9.2 Etvax: Scandinavian Biopharma
9.3 Bismuth Subsalicylate: Procter and Gamble
10 Traveler's Diarrhea 7 Major Market Analysis
11 Traveler's Diarrhea United States Market Outlook
12 Traveler's Diarrhea EU-5 Countries Market Outlook
12.5 United Kingdom
13 Traveler's Diarrhea Japan Market Outlook
14 Traveler's Diarrhea Market Drivers
15 Traveler's Diarrhea Market Barriers
16.1 Report Methodology
17 DelveInsight Capabilities
19 About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.